DrugPatentWatch Database Preview
OPDIVO Drug Profile
Summary for Tradename: OPDIVO
| Patents: | 106 |
| Applicants: | 1 |
| BLAs: | 2 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for OPDIVO |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for OPDIVO |
Recent Clinical Trials for OPDIVO
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | Phase 2 |
| Sun Yat-sen University | Phase 2 |
| Istari Oncology, Inc. | Phase 1 |
Recent Litigation for OPDIVO
Identify key patents and potential future biosimilar entrants
PTAB Litigation
| Petitioner | Date |
|---|---|
| Genome & Company | 2018-10-02 |
Pharmacology for OPDIVO
| Mechanism of Action | Programmed Death Receptor-1-directed Antibody Interactions |
Patent Text Search: US Patents for OPDIVO
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | 2035-06-26 | RX | search | |
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | Oncomatryx Biopharma, S.L. (Derio, ES) | 2034-02-06 | RX | search | |
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | Biodesix, Inc. (Boulder, CO) | 2035-07-13 | RX | search | |
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN) | 2034-10-30 | RX | search | |
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2032-08-30 | RX | search | |
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | Bristol-Myers Squibb Company (Princeton, NJ) | 2032-05-15 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for OPDIVO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2006502699 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2015103989 | Start Trial |
| Canada | 2787753 | Start Trial |
| Japan | 2015511225 | Start Trial |
| Japan | 2019108373 | Start Trial |
| South Korea | 20160133510 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
